A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05600777

Status	RECRUITING
Phase	Phase 3
Sponsor	Bellus Health Inc. - a GSK company
Enrollment	975 participants

Key Eligibility Criteria

Inclusion (3)

- Capable of giving signed informed consent
- Refractory chronic cough (including unexplained chronic cough) for at least one year
- Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose

Exclusion (8)

- Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
- Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
- Respiratory tract infection within 4 weeks before screening
- Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
- History of malignancy in the last 5 years

... and 3 more (see full listing online)

Locations (242 total)

GSK Investigational Site, Foley, Alabama, United States
GSK Investigational Site, Phoenix, Arizona, United States
GSK Investigational Site, Los Angeles, California, United States
... and 239 more locations